NeuroproteXeon (“NPXe”) Announces Hiring of Vice President Clinical Development
NeuroproteXeon, Inc. is pleased to announce the appointment of Barbara Bunger, Ph.D. as VP of Clinical Development effective May 20, 2019. Dr. Bunger will manage the XePOHCAS trial, site recruitment, and manage the US Clinical Monitor, Dr. Doron Feldman, and the EU Clinical Monitor. In addition, in conjunction with Rich Robel, VP Engineering, she will co-ordinate clinical trial support from our commercial partners.
Dr. Bunger is a 30-year industry veteran with experience spanning pharmaceutical, biologic, and medical device development working in both start-up and large corporations.
Her experience includes all aspects of clinical evidence development needed to support regulatory approvals, drive market adoption, and secure optimal reimbursement. Barbara has a proven track record of leadership in the successful planning and execution of US and international clinical programs. She has held progressive positions in the industry across clinical and regulatory affairs. Prior to joining NeuroproteXeon, Barbara was Head of Regulatory and Clinical Affairs Strategic Development at Philips’ emerging businesses division and previously held similar leadership positions at SI Bone, Inc., and Medtronic.
Barbara holds a Bachelor of Science in Nursing, a Master of Science in Biology, and a Ph.D. in Health Administration and Health Economics.
Please join us in welcoming Barbara to our team. She and her clinical development team will report to me during the site rollout period.
Cc: Paul Harder, Chairman